Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price boosted by investment analysts at Bank of America ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Costco ...
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
The US Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
Highlights,Multiple financial firms have provided positive ratings for Axsome Therapeutics, reflecting confidence in the ...
Highlights,Oppenheimer raised its price expectation for Lululemon, reflecting financial performance adjustments.,Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback